-
Uncategorized6 days agoSTAT+: HIV resurgence is feared as global funding to combat the disease falls 18%
The world risks a resurgence of the HIV epidemic after international financing to combat the infectious disease suffered a “profound shock” last year, according to a...
-
Uncategorized6 days ago
Solving the Mystery of Why Blocking and Stimulating a Brain Receptor Helps Weight Loss
Researchers headed by a team at the Institute of Metabolic Science, University of Cambridge, have solved the mystery of why both stimulating and blocking a particular...
-
Uncategorized6 days agoSTAT+: Pharma’s drug spending deflection
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. Hello! Wanna drop some cars in an open pasture? The internet...
-
Uncategorized7 days agoMapLight dives despite positive data for schizophrenia drug
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers’ Cobenfy.
-
Uncategorized7 days ago
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy
In briefing documents published Monday ahead of an advisory committee meeting for deramiocel, the FDA disagreed with Capricor’s assertion that a Phase 3 trial met its...
-
Uncategorized7 days ago
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
While MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb’s Cobenfy is likely to hold its...
-
Uncategorized7 days ago
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
Despite a Phase 3 miss, Gossamer Bio is full steam ahead for its lung disease asset, pointing to previous “review issues” at the FDA as one...
-
Uncategorized7 days ago
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
After leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.
-
Uncategorized7 days ago
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
Rare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III (RACC) to fund a rare...
-
Uncategorized7 days agoSTAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive
Sarepta Therapeutics, the bruised maker of Duchenne muscular dystrophy treatments, on Monday named Michael Severino, formerly the CEO of Tessera Therapeutics, as its new chief executive,...
StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel
STAT+: Senate measure would block Trump plan to politicize federal grants, for now
